Chinese Herb Shows Promise for Diabetic Kidney Disease

A study from China has used some of the most advanced cellular imaging technology available to investigate how a traditional medicinal plant — Abelmoschus manihot (commonly known as sunset muskmallow) — may help slow or treat diabetic kidney disease (DKD). Published in the journal iMeta in 2025, the research from China Pharmaceutical University in Nanjing offers a fascinating look at how ancient herbal remedies and modern molecular science can work together.

What Did the Researchers Do?

Scientists extracted the active compounds from Abelmoschus manihot — a group of plant chemicals called total flavones (TFA) — and tested them in diabetic mice that naturally develop kidney disease similar to humans. Using a groundbreaking technology called Spatial Enhanced Resolution Omics-sequencing (at an incredibly fine resolution of just 0.25 micrometers), combined with single-cell RNA sequencing, the team created the world's first detailed, cell-by-cell molecular map of how this herbal treatment acts inside diabetic kidneys.

They compared three groups: mice treated with TFA alone, mice treated with irbesartan (IRB) — a standard blood-pressure and kidney-protecting medication widely used in the US — and mice treated with both together.

What Did They Find?

Remarkably, TFA alone performed comparably to TFA combined with irbesartan in protecting the kidneys. Through genome-wide analysis and computer-simulated molecular docking, researchers identified the specific kidney receptors and genetic regulators that TFA appears to target, including proteins called Itga3, Itga5, and Tgfbr1, along with regulatory molecules Jun, Junb, and Stat1. These are known players in kidney inflammation and scarring — two key processes that drive DKD progression.

In the US, DKD affects approximately 1 in 3 adults with diabetes, and blood sugar targets for kidney protection are typically set at an A1C below 7% (average blood glucose of roughly 154 mg/dL, or 8.6 mmol/L). Current American Diabetes Association (ADA) guidelines emphasize medications like ACE inhibitors, ARBs (such as irbesartan), SGLT2 inhibitors, and GLP-1 receptor agonists for kidney protection. The finding that a plant-based compound may match the effectiveness of an ARB is scientifically significant.

Why This Matters for US Patients

Diabetic kidney disease remains one of the leading causes of kidney failure in the United States, and many patients do not respond fully to existing treatments — or experience side effects that limit their use. This Chinese research highlights a completely different molecular pathway that could eventually lead to new drug targets or complementary therapies.

While Abelmoschus manihot extract (sold in China as Huangkui capsules) is not currently FDA-approved or available as a standard treatment in the US, the molecular targets identified in this study — particularly in kidney inflammation and fibrosis — are actively being researched by American pharmaceutical companies. Understanding how a natural compound affects these same pathways may accelerate drug development.

Important note for patients: Do not attempt to self-treat diabetic kidney disease with herbal supplements without speaking to your doctor. Always follow your care team's guidance on kidney protection strategies.

Citation

Wu, Tang, Yu et al. "Single-cell spatial transcriptomics reveals potential molecular mechanisms of Abelmoschus manihot (L.) medic in treating diabetic kidney disease." iMeta, 2025. DOI: 10.1002/imt2.70099. PMID: 41472859.